Supplemental Postoperative Bupivacaine Following Non-Surgical Endodontic Treatment

Description

The study will investigate the impact of an additional injection of long-acting anesthetic on pain level, quality of life, and use of pain medication after a nonsurgical endodontic treatment. The long-acting anesthetic will be compared to a mock injection group and a group with no additional anesthetic to determine any differences in effects.

Conditions

Pain Assessment, Quality of Life (QOL), Analgesic Use

Talk to us

Study Overview

On this page

Study Details

Study overview

The study will investigate the impact of an additional injection of long-acting anesthetic on pain level, quality of life, and use of pain medication after a nonsurgical endodontic treatment. The long-acting anesthetic will be compared to a mock injection group and a group with no additional anesthetic to determine any differences in effects.

The Effects of Supplemental Postoperative 0.5% Bupivacaine With 1:200,000 Epinephrine Following Non-Surgical Endodontic Treatment on Patients' Quality of Life, Pain, and Analgesic Consumption

Supplemental Postoperative Bupivacaine Following Non-Surgical Endodontic Treatment

Condition
Pain Assessment
Intervention / Treatment

-

Contacts and Locations

New York

New York University College of Dentistry, New York, New York, United States, 10010

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Medical ASA Class I or II
  • 2. Patients above 18 years old
  • 3. Patients with a blood pressure below 160/100
  • 4. Patients who are treatment planned and have agreed to have emergency endodontic therapy or non-surgical root canal therapy with a pulpal diagnosis of symptomatic irreversible pulpitis according to the AAE Glossary of Endodontic Terms.
  • 5. Patients must be able to comprehend and complete all study protocols, written consent, and questionnaires in English.
  • 1. Medical ASA III or above
  • 2. Patients who reported the use of tobacco or nicotine-containing products such as vapes, e-cigarettes, gums, or pouches and will not in the 48 hours following treatment
  • 3. Patients who reported the use of any marijuana products or illicit drugs in the 48 hours prior to treatment and will not in the next 48 hours.
  • 4. Patients who have taken opioids to control pain.
  • 5. Pregnant patients
  • 6. Patients with a blood pressure of 160/100 or greater
  • 7. Patients with a known hypersensitivity or allergy to any local anesthetic agent of the amide group, or any other components of the two anesthetic solutions such as epinephrine, sodium metabisulfite used in the study.
  • 8. Patients who have more than one tooth with odontogenic pain at the time of the screening.
  • 9. Patients who are unable to consent and do not understand or are unable to read the questionnaires.
  • 10. Patients who have had 4 1.7 ml carpules or more of anesthetic (Lidocaine and/ or Septocaine, 1:100,000) during standard care of treatment.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

New York University,

Study Record Dates

2025-12-01